SavedAdd your journal

Journals / EMU Journal of Pharmaceutical Sciences / 2026 / Volume: 9 Issue: 2

Identification of Novel N-(Aryl)-3-(N-benzylsulfamoyl)benzamides as NAMPT Activators

Fikriye Özgencil(GAZI UNIVERSITY, FACULTY OF PHARMACY, DEPARTMENT OF PROFESSIONAL PHARMACEUTICAL SCIENCES, DEPARTMENT OF PHARMACEUTICAL CHEMISTRY)0000-0003-3664-4150
Gökçen Eren(GAZI UNIVERSITY, FACULTY OF PHARMACY, DEPARTMENT OF PROFESSIONAL PHARMACEUTICAL SCIENCES, DEPARTMENT OF PHARMACEUTICAL CHEMISTRY)0000-0002-3420-607X
Pages
—
Publication Date
2026-09-30
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In addition, molecular docking studies were conducted within both the catalytic and allosteric sites of NAMPT, and the resulting binding patterns were analyzed to correlate structural differences with the observed in vitro NAMPT activity, highlighting the significance of molecular interactions.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Nicotinamide adenine dinucleotide (NAD⁺) plays a central role in numerous physiological processes, and maintaining or increasing cellular NAD⁺ levels has emerged as a promising strategy for promoting healthy aging.
📊
Key Findings & Data:Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme in the NAD+ salvage pathway, which makes it an attractive target for the treatment of many diseases associated with NAD+ depletion, such as inflammation, neurodegenerative, and metabolic diseases.
💡
Conclusion & Impact:In addition, molecular docking studies were conducted within both the catalytic and allosteric sites of NAMPT, and the resulting binding patterns were analyzed to correlate structural differences with the observed in vitro NAMPT activity, highlighting the significance of molecular interactions.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:NAMPT · activator · molecular docking

Abstract

Nicotinamide adenine dinucleotide (NAD⁺) plays a central role in numerous physiological processes, and maintaining or increasing cellular NAD⁺ levels has emerged as a promising strategy for promoting healthy aging. Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme in the NAD+ salvage pathway, which makes it an attractive target for the treatment of many diseases associated with NAD+ depletion, such as inflammation, neurodegenerative, and metabolic diseases. Herein, we report the synthesis and in vitro biological evaluation of STA1-STA3, which increased NAMPT activation by 2- to 38-fold. In addition, molecular docking studies were conducted within both the catalytic and allosteric sites of NAMPT, and the resulting binding patterns were analyzed to correlate structural differences with the observed in vitro NAMPT activity, highlighting the significance of molecular interactions.

🔖

Cite This Article

Özgencil, F., Eren, G. (2026). Identification of Novel N-(Aryl)-3-(N-benzylsulfamoyl)benzamides as NAMPT Activators. EMU Journal of Pharmaceutical Sciences, Volume: 9 Issue: 2. https://doi.org/10.54994/emujpharmsci.1955775

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (38)

  1. Audrito V, Manago A, Gaudino F, Sorci L, Messana VG, et al. (2019). "NAD-Biosynthetic and Consuming Enzymes as Central Players of Metabolic Regulation of Innate and Adaptive Immune Responses in Cancer”. Front Immunol 10: 1720.
  2. Canto C, Menzies KJ, Auwerx J (2015). "NAD(+) Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus”. Cell Metab 22(1): 31-53.
  3. Chini EN (2009). "CD38 as a regulator of cellular NAD: a novel potential pharmacological target for metabolic conditions”. Curr Pharm Des 15(1): 57-63.
  4. Conlon N, Ford D (2022). "A systems-approach to NAD+ restoration”. Biochem Pharmacol 198: 114946.
  5. Croteau DL, Fang EF, Nilsen H, Bohr VA (2017). "NAD(+) in DNA repair and mitochondrial maintenance”. Cell Cycle 16(6): 491-492.
  6. Essuman K, Summers DW, Sasaki Y, Mao X, DiAntonio,A, et al. (2017). "The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD(+) Cleavage Activity that Promotes Pathological Axonal Degeneration”. Neuron 93(6): 1334-1343.e5.
  7. Friesner R A, Murphy RB, Repasky MP, Frye LL, Greenwood JR, et al. (2006). "Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein−Ligand Complexes”. Journal of Medicinal Chemistry 49(21): 6177-6196.
  8. Gardell SJ, Hopf M, Khan A, Dispagna M, Hampton Sessions E, et al. (2019). "Boosting NAD+ with a small molecule that activates NAMPT”. Nature Communications 10(1): 3241.
  9. Ghanem MS, Monacelli F, Nencioni A 2021. "Advances in NAD-Lowering Agents for Cancer Treatment”. Nutrients 13(5): 1665.
  10. Gordon-Blake J, Ratia K, Weidig V, Velma GR, Ackerman-Berrier M, et al. (2024). "Nicotinamide Phosphoribosyltransferase Positive Allosteric Modulators Attenuate Neuronal Oxidative Stress”. ACS Medicinal Chemistry Letters 15(2): 205-214.
  11. Graeff R, Liu Q, Kriksunov IA, Kotaka M, Oppenheimer N, et al. (2009). "Mechanism of cyclizing NAD to cyclic ADP-ribose by ADP-ribosyl cyclase and CD38”. J Biol Chem 284(40): 27629-36.
  12. Iqbal T, Nakagawa T (2024). "The therapeutic perspective of NAD(+) precursors in age-related diseases”. Biochem Biophys Res Commun 702: 149590.
  13. Iwatani Y, Hayashi H, Minamisawa M, Hasegawa S, Moriyama Y, et al. (2026). "Protective effects of the NAMPT activator P7C3-A20 on mouse neuronal injury in diabetic stroke: The role of intracellular NAMPT and SIRT1/FoxO3a signaling”. Biomed Pharmacother 194: 118963.
  14. Jadeja RN, Thounaojam MC, Bartoli M, Martin PM (2020). "Implications of NAD+ Metabolism in the Aging Retina and Retinal Degeneration”. Oxid Med Cell Longev 2020(1): 2692794.
  15. Jiang Z, Li YX, Zhao DD, Hu YT, Xiao LZ et al. (2026). "A novel NAMPT activator ameliorates obesity by repressing ACSL1-dependent lipid synthesis”. Acta Pharmaceutica Sinica B.
  16. Katsyuba E, Romani M, Hofer D, Auwerx J (2020). "NAD(+) homeostasis in health and disease”. Nat Metab 2(1): 9-31.
  17. Kim MK, Lee JH, Kim H, Park SJ, Kim SH, et al. (2006). "Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866”. J Mol Biol 362(1): 66-77.
  18. Li Y, Yang S, Fang Y, Li Y, Xia Z, et al. (2026). "Discovery of a Nicotinamide Phosphoribosyltransferase (NAMPT) Activator for Improving Muscle Function and Alleviating Fatigue”. Journal of Medicinal Chemistry.
  19. Luengo A, Li Z, Gui DY, Sullivan LB, Zagorulya M, et al. (2021). "Increased demand for NAD(+) relative to ATP drives aerobic glycolysis”. Mol Cell 81(4): 691-707.e6.
  20. Mischley LK, Shankland E, Liu SZ, Bhayana S, Fox DJ, et al. (2023). "ATP and NAD(+) Deficiency in Parkinson's Disease”. Nutrients 15(4).
  21. Murata MM, Kong X, Moncada E, Chen Y, Imamura H, et al. (2019). "NAD+ consumption by PARP1 in response to DNA damage triggers metabolic shift critical for damaged cell survival”. Mol Biol Cell 30(20): 2584-2597.
  22. Navarro MN, Gómez de las Heras MM, Mittelbrunn M (2022). "Nicotinamide adenine dinucleotide metabolism in the immune response, autoimmunity and inflammageing”. Br J Pharmacol 179(9): 1839-1856.
  23. Obrador E, Salvador-Palmer R, López-Blanch R, Dellinger RW, Estrela JM (2021). "NAD(+) Precursors and Antioxidants for the Treatment of Amyotrophic Lateral Sclerosis”. Biomedicines 9(8).
  24. Okabe K, Yaku K, Tobe K, Nakagawa T (2019). "Implications of altered NAD metabolism in metabolic disorders”. J Biomed Sci 26(1): 34.
  25. Ozgencil F, Eren G, Ozkan Y, Guntekin-Ergun S, Cetin-Atalay R (2020). "Identification of small-molecule urea derivatives as novel NAMPT inhibitors via pharmacophore-based virtual screening”. Bioorganic & Medicinal Chemistry 28(1): 115217.
  26. Ozgencil F, Gunindi HB, Eren G (2024). "Dual-targeted NAMPT inhibitors as a progressive strategy for cancer therapy”. Bioorganic Chemistry 149: 107509.
  27. Poltronieri P, Celetti A, Palazzo L (2021). "Mono(ADP-ribosyl)ation Enzymes and NAD(+) Metabolism: A Focus on Diseases and Therapeutic Perspectives”. Cells 10(1).
  28. Ralto KM, Rhee EP, Parikh SM (2020). "NAD+ homeostasis in renal health and disease”. Nature Reviews Nephrology 16(2): 99-111.
  29. Ratia KM, Shen Z, Gordon-Blake J, Lee H, Laham MS, et al. (2023). "Mechanism of Allosteric Modulation of Nicotinamide Phosphoribosyltransferase to Elevate Cellular NAD”. Biochemistry 62(4): 923-933.
  30. Tang S, Garzon Sanz M, Smith O, Krämer A, Egbase D, et al. (2023). "Chemistry-led investigations into the mode of action of NAMPT activators, resulting in the discovery of non-pyridyl class NAMPT activators”. Acta Pharmaceutica Sinica B 13(2): 709-721.
  31. Velma GR, Krider IS, Alves ETM, Courey JM, Laham MS, et al. (2024). "Channeling Nicotinamide Phosphoribosyltransferase (NAMPT) to Address Life and Death”. Journal of Medicinal Chemistry 67(8): 5999-6026.
  32. Wang G, Han T, Nijhawan D, Theodoropoulos P, Naidoo J, et al. (2014). "P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage”. Cell 158(6): 1324-1334.
  33. Wang L, Liu M, Zu Y, Yao H, Wu C, et al. (2022). "Optimization of NAMPT activators to achieve in vivo neuroprotective efficacy”. European Journal of Medicinal Chemistry 236: 114260.
  34. Wang X, He HJ, Xiong X, Zhou S, Wang WW, et al. (2021). "NAD(+) in Alzheimer's Disease: Molecular Mechanisms and Systematic Therapeutic Evidence Obtained in vivo”. Front Cell Dev Biol 9: 668491.
  35. Wu X, Fan X, Plan M, Stark T, McCubbin T, et al. (2025). "Altered nicotinamide adenine dinucleotide metabolism drives cartilage degeneration and osteoarthritis”. Clinical and Translational Medicine 15(11): e70513.
  36. Yang S, Sun D, Wu Y, Chen S, Guo Y, et al. (2024). "Discovery of a Potent Nicotinamide Phosphoribosyltransferase Activator for Improving Aging-associated Dysfunctions”. J Med Chem 67(5): 4120-4130.
  37. Yang Y, Sauve AA (2016). "NAD(+) metabolism: Bioenergetics, signaling and manipulation for therapy”. Biochim Biophys Acta 1864(12): 1787-1800.
  38. Yao H, Liu M, Wang L, Zu Y, Wu C, et al. (2022). "Discovery of small-molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and their preclinical neuroprotective activity”. Cell Res 32(6): 570-584.